Skip to main content
SpringerLink
Log in

Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The epidermal growth factor receptor (EGFR) mutation is the first recognized molecular target in non-small cell lung cancer that makes personalized therapy feasible. This molecular alteration has been demonstrated to be more frequent in Asians, non-smokers and patients with adenocarcinoma histology. Several retrospective and subgroup analyses of phase III trials have shown the single agent, erlotinib, to be associated with higher response rates and longer progression-free survival in patients harbouring an EGFR mutation. Two prospective randomized phase III studies from China and Europe have confirmed the role of first-line erlotinib in patients with the mutations. Erlotinib has also been evaluated in combination with chemotherapy in either a concurrent or intercalated regimen. Earlier trials were limited by little information on the EGFR mutational status of the enrolled patients, and an ongoing phase III trial with translational biomarker analysis will provide more comprehensive data on the combination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39

    Article  PubMed  CAS  Google Scholar 

  2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500

    Article  PubMed  CAS  Google Scholar 

  3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57

    Article  PubMed  CAS  Google Scholar 

  4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previsouly treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9464): 1527–37

    Article  PubMed  CAS  Google Scholar 

  5. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Ins 2005; 97: 339–46

    Article  CAS  Google Scholar 

  6. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817–24

    Article  PubMed  CAS  Google Scholar 

  7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123–32

    Article  PubMed  CAS  Google Scholar 

  8. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erltotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4286–75

    Google Scholar 

  9. Zhou C, Wu Y-L, Chen G, et al. OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 2010; 21 Suppl. 8: viii6 (Abstract LBA13)

    Google Scholar 

  10. Mok T, Wu YL, Au JS, et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian Patients with advanced non-small-cell lung cancer. J Thoracic Oncol 2010; 5(10): 1609–15

    Article  Google Scholar 

  11. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361(10): 958–67

    Article  PubMed  CAS  Google Scholar 

  12. Gervais R, Rosell R, Vergnenegre A, et al. The EURTAC (European Tarceva vs Chemotherapy) study: Interim results of a phase III randomized trial of erlotinib vs chemotherapy in advanced non-small-cell lung cancer patients with epidermal growth factor receptor activating mutations. J Thor Oncol 2011; 6 Suppl. 6: S314

    Google Scholar 

  13. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J Clin Oncol 2011, 29(21): 2866–74

    Article  PubMed  CAS  Google Scholar 

  14. Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. 13th World Conference on Lung Cancer; 2009; San Francisco, CA, USA

  15. Mitsudomi T, Morita S, Yatabe Y, et al., West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8

    Article  PubMed  CAS  Google Scholar 

  16. Maemondo M, Inoue A, Kobayashi K, et al., North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8

    Article  PubMed  CAS  Google Scholar 

  17. Rosell R, Carcerney F, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology 2012; 13(2): 239–46

    Article  PubMed  CAS  Google Scholar 

  18. Paz-Ares L, Soulie`res D, Melezínek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010; 14(1–2): 51–69

    Article  PubMed  CAS  Google Scholar 

  19. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 1. J Clin Oncol 2004; 22: 777–84

    Article  PubMed  CAS  Google Scholar 

  20. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 2. J Clin Oncol 2004; 22: 785–94

    Article  PubMed  CAS  Google Scholar 

  21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892–9

    Article  PubMed  CAS  Google Scholar 

  22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545–52

    Article  PubMed  CAS  Google Scholar 

  23. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23(25): 5900–9

    Article  PubMed  CAS  Google Scholar 

  24. Janne PA, Wang XF, Socinski M A, et al. Randomized phase II trial of erlotinib alone or in combination with carboplatin/paclitaxel in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. ASCO MEETING ABSTRACTS Jun 14, 2010: 7503

  25. Piperdi B, Ling Y, Kroog G, et al. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. J Clin Oncol 2004; 23: 620, (suppl; abstr 7028)

    Google Scholar 

  26. Davies AM, Ho C, Lara Jr PN, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 385–8

    Article  PubMed  CAS  Google Scholar 

  27. Li T, Ling Y-H, Goldman I, et al. Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells. Clin Cancer Res 2007; 13: 3413–22

    Article  PubMed  CAS  Google Scholar 

  28. Davies AM, Hesketh PJ, Beckett L, et al. Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism. J Clin Oncol 2007; 25: 413s, (suppl; abstr 7618)

    Google Scholar 

  29. Davies AM, Ho C, Beckett L, et al. Intermittent erlotinib (ERL) in combination with pemetrexed (PEM): Phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol 2008; 26: 1431s, (suppl; abstr 8032)

    Google Scholar 

  30. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11(6): 521–9

    Article  PubMed  CAS  Google Scholar 

  31. Meany HJ, Fox E, McCully C, et al. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol 2008; 62(3): 387–92

    Article  PubMed  CAS  Google Scholar 

  32. Broniscer A, Panetta JC, O’Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13(5): 1511–15

    Article  PubMed  CAS  Google Scholar 

  33. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010; 5(7): 950–5

    PubMed  Google Scholar 

  34. Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010; 12(1): 95–103

    Article  PubMed  CAS  Google Scholar 

  35. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005; 11(21): 7841–50

    Article  PubMed  CAS  Google Scholar 

  36. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57(21): 4838–48

    PubMed  CAS  Google Scholar 

  37. Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009; 65(3): 351–4

    Article  PubMed  Google Scholar 

  38. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4(11): 1415–19

    Article  PubMed  Google Scholar 

  39. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37(3): 624–31

    Article  PubMed  CAS  Google Scholar 

  40. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292–302

    Article  PubMed  CAS  Google Scholar 

  41. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor kinase inhibitor, in patients withadvanced solid malignancies. J Clin Oncol 2011; 19(13): 3267–79

    Google Scholar 

  42. Cho BC, Im C, Park M, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25(18): 2528–33

    Article  PubMed  CAS  Google Scholar 

  43. Vasile E, Tibaldi C, Falcone A. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients? Ann Oncol 2009; 20(4): 790–1

    Article  PubMed  CAS  Google Scholar 

  44. Lee DH, Kim S-W, Suh C, et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008 Jul; 19: 2039–42

    Article  PubMed  CAS  Google Scholar 

  45. Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small-cell lung cancer. Lung Cancer 2010; 68(1): 99–104

    Article  PubMed  Google Scholar 

  46. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 768–92

    Article  Google Scholar 

  47. Engelman JA, Zejnullah K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039–43

    Article  PubMed  CAS  Google Scholar 

  48. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13(17): 5150–5

    Article  PubMed  CAS  Google Scholar 

  49. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010 10; 28(2): 357–60

    Article  PubMed  CAS  Google Scholar 

  50. Mok TSK. Personalized medicine in lung cancer: What we need to know. Nat Rev Clin Oncol 8(11): 661–8

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Southern China, The Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital, Hong Kong, China

    Tony S. K. Mok

  2. Istituto Toscano Tumori, Medical Oncology, Livorno Civil Hospital, Livorno, Italy

    Manolo D’arcangelo

  3. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

    Raffaele Califano

Authors
  1. Tony S. K. Mok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manolo D’arcangelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaele Califano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tony S. K. Mok.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mok, T.S.K., D’arcangelo, M. & Califano, R. Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation. Drugs 72 (Suppl 1), 3–10 (2012). https://doi.org/10.2165/1163014-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1163014-S0-000000000-00000

Keywords

Search

Navigation